MarketLens
Sign Up

Amgen's Biotech Crossroads: Congressional Divergence Amid Patent Cliffs and Pipeline Promise

4 months ago
SHARE THIS ON:

Amgen's Biotech Crossroads: Congressional Divergence Amid Patent Cliffs and Pipeline Promise

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 week ago

Amgen's Dividend Has Grown 800% Since 2011. Here's What It Pays Today

Amgen has raised its dividend every year since 2011, but the pace of increases is slowing as patent cliffs and drug price controls approach. The next raise, due soon, will test whether the streak hold...
Stock News•2 months ago

Amgen Highlights MariTide, IMDELLTRA Pipeline Progress and Growth Priorities

Amgen highlighted MariTide and IMDELLTRA pipeline progress and growth priorities at a Morgan Stanley conference, with new CFO Thomas Dittrich emphasizing execution, financial discipline, and cash-on-c...
Stock News•2 months ago

Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal

Amgen shares fell after Novartis' pelacarsen missed its Phase III goal, raising investor concern over whether Amgen's olpasiran can deliver positive Phase III data.

Breaking News

View All →

Top Headlines

View More →
Stock News•2 hours ago

Cisco Stock Fell 15.5% Despite Its Strongest Growth in 15 Years. Is the Dividend Safe?

Stock News•2 hours ago

Prediction: This Will Be Nvidia's Stock Price in 2027 After Its Phenomenal Q3 Results

Stock News•2 hours ago

GOOGL, GOOG FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Alphabet Inc. Investors to Secure Counsel Before Important December 1 Deadline in Securities Class Action - GOOGL, GOOG

Stock News•3 hours ago

The S&P 500 Is Now Below Every Wall Street Year-End Target for 2026

Stock News•3 hours ago

The S&P 500 Is Having the Longest Losing Streak Since February 2020